Squarepoint
CRSP icon

Squarepoint’s CRISPR Therapeutics CRSP Stock Holding History

Squarepoint’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
4,200
-5,700
-58% -$300K ﹤0.01% 3984
2026
Q1 		$471K Sell
9,900
-61,600
-86% -$3.25M ﹤0.01% 3373
2025
Q4 		$3.75M Sell
71,500
-36,100
-34% -$2.16M ﹤0.01% 1643
2025
Q3 		$6.97M Buy
107,600
+96,900
+906% +$5.56M 0.01% 1267
2025
Q2 		$520K Sell
10,700
-3,600
-25% -$139K ﹤0.01% 3246
2025
Q1 		$487K Sell
14,300
-26,500
-65% -$1.12M ﹤0.01% 3322
2024
Q4 		$1.61M Buy
40,800
+29,100
+249% +$1.37M ﹤0.01% 2615
2024
Q3 		$550K Sell
11,700
-100
-0.8% -$5.07K ﹤0.01% 3020
2024
Q2 		$637K Sell
11,800
-4,200
-26% -$243K ﹤0.01% 2896
2024
Q1 		$1.09M Sell
16,000
-3,100
-16% -$222K ﹤0.01% 2528
2023
Q4 		$1.2M Buy
+19,100
New +$1.06M ﹤0.01% 2401
2023
Q3 		– Sell
-10,000
Closed -$561K – 3847
2023
Q2 		$561K Sell
10,000
-1,000
-9% -$56.7K ﹤0.01% 2554
2023
Q1 		$498K Sell
11,000
-20,700
-65% -$1.01M ﹤0.01% 2299
2022
Q4 		$1.29M Sell
31,700
-300
-0.9% -$15.9K 0.01% 1643
2022
Q3 		$2.09M Buy
+32,000
New +$2.32M 0.01% 1295

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's CRSP Position: Q2 2026 in Review

Squarepoint increased its CRISPR Therapeutics (CRSP) stake by 87% in Q2 2026, buying an estimated $7.02M and bringing the position to 286,789 shares worth $15.6M. The position accounts for 0.02% of the portfolio, ranked #826.

Squarepoint first reported a position in CRSP in Q1 2018 and has held it in 24 quarters since. The position peaked at $30.5M in Q4 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Squarepoint held 286,789 shares of CRISPR Therapeutics worth $15.6M as of Q2 2026.
  • Squarepoint bought 133,214 CRISPR Therapeutics shares in Q2 2026, an estimated $7.02M.
  • CRISPR Therapeutics made up 0.02% of Squarepoint's portfolio in Q2 2026, its #826 holding.
  • Squarepoint first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • Squarepoint's CRISPR Therapeutics position peaked at $30.5M in Q4 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.